Skip to main content
Livermore
Livermore
ZHEN

TCG Crossover Management, LLC

SEC CIK
0001839948
Latest filing
Aug 14, 2026

Holdings in Q3 2025

Holdings as of Sep 30, 2025, filed Nov 17, 2025. Long positions only; changes compare share counts with Q2 2025.

Institution overview
Positions
40
+3 vs. Q2 2025
Portfolio value
$2.03B
+$1.16B (+132.2%) vs. Q2 2025
Filed
Nov 17, 2025
SEC
Holdings of TCG Crossover Management, LLC in Q3 2025
SecurityClassSharesValue% of portfolioShare changeActionHistory
ABVXAbivax S.A.SPONSORED ADS7,111,596$603.8M29.7%+1,055,000+17.4%AddedHistory
CGONCG Oncology, Inc.COM3,670,206$147.8M7.3%00.0%UnchangedHistory
COGTCogent Biosciences, Inc.COM6,798,162$97.6M4.8%−166,213−2.4%ReducedHistory
AMLXAmylyx Pharmaceuticals, Inc.COM6,243,812$84.9M4.2%+300,000+5.0%AddedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS3,136,480$76.1M3.7%+245,664+8.5%AddedHistory
TNGXTango Therapeutics, Inc.COM8,536,196$71.7M3.5%−2,199,804−20.5%ReducedHistory
OCULOcular Therapeutix, IncCOM6,117,232$71.5M3.5%+798,084+15.0%AddedHistory
DNTHDianthus Therapeutics, Inc.COM1,676,624$66.0M3.2%+175,000+11.7%AddedHistory
TRMLTourmaline Bio, Inc.COM1,311,783$62.7M3.1%−165,810−11.2%ReducedHistory
DYNDyne Therapeutics, Inc.COM4,615,144$58.4M2.9%+848,484+22.5%AddedHistory
AGIOAgios Pharmaceuticals, Inc.COM1,430,041$57.4M2.8%+733,038+105.2%AddedHistory
EYPTEyePoint, Inc.COM NEW3,572,335$50.9M2.5%00.0%UnchangedHistory
FULCFulcrum Therapeutics, Inc.COM5,250,000$48.3M2.4%00.0%UnchangedHistory
SVRASavara IncCOM12,362,205$44.1M2.2%00.0%UnchangedHistory
RAPTRAPT Therapeutics, Inc.COM NEW1,636,275$42.2M2.1%00.0%UnchangedHistory
TYRATyra Biosciences, Inc.COM2,898,103$40.5M2.0%00.0%UnchangedHistory
UPBUpstream Bio, Inc.COM2,117,103$39.8M2.0%−684,660−24.4%ReducedHistory
LQDALiquidia CorpCOM NEW1,710,084$38.9M1.9%+1,710,084NewHistory
IRONDisc Medicine, Inc.COM465,257$30.7M1.5%00.0%UnchangedHistory
GPCRStructure Therapeutics Inc.SPONSORED ADS1,063,000$29.8M1.5%00.0%UnchangedHistory
XNCRXencor IncCOM2,452,138$28.8M1.4%00.0%UnchangedHistory
LBRXLB Pharmaceuticals IncCOM SHS1,745,016$27.6M1.4%+1,745,016NewHistory
RVMDRevolution Medicines, Inc.COM436,473$20.4M1.0%+436,473NewHistory
ATXSAstria Therapeutics, Inc.COM2,761,861$20.1M1.0%00.0%UnchangedHistory
KRROKorro Bio, Inc.COM416,301$19.9M1.0%+416,301NewHistory
KODKodiak Sciences Inc.COM1,145,538$18.8M0.9%00.0%UnchangedHistory
SYRESpyre Therapeutics, Inc.COM NEW1,100,582$18.4M0.9%+1,100,582NewHistory
SLNSilence Therapeutics plcADS3,033,560$15.7M0.8%00.0%UnchangedHistory
URGNUroGen Pharma Ltd.COM717,347$14.3M0.7%+717,347NewHistory
ARVNArvinas, Inc.COM1,617,365$13.8M0.7%+1,617,365NewHistory
MNPRMonopar TherapeuticsCOM NEW153,000$12.5M0.6%+153,000NewHistory
MBXMBX Biosciences, Inc.COM650,000$11.4M0.6%00.0%UnchangedHistory
VTGNVistagen Therapeutics, Inc.COM2,676,580$9.50M0.5%00.0%UnchangedHistory
RLAYRelay Therapeutics, Inc.COM1,810,351$9.45M0.5%+1,810,351NewHistory
ADVMAdverum Biotechnologies, Inc.COM NEW1,668,174$7.56M0.4%−128,308−7.1%ReducedHistory
AVTXAvalo Therapeutics, Inc.COM NEW483,000$6.14M0.3%00.0%UnchangedHistory
ADCTADC Therapeutics SASHS1,390,175$5.56M0.3%+1,390,175NewHistory
PEPGPepGen Inc.COM1,200,000$5.54M0.3%+1,200,000NewHistory
TRDAEntrada Therapeutics, Inc.COM584,955$3.39M0.2%00.0%UnchangedHistory
VTYXVentyx Biosciences, Inc.COM316,195$983.4K<0.1%00.0%UnchangedHistory

Sold out since Q2 2025 (8)

Positions held at the end of Q2 2025 that are gone from this filing.

Positions of TCG Crossover Management, LLC sold out since Q2 2025
SecurityClassShares in Q2 2025Value in Q2 2025% of portfolio in Q2 2025History
CDTXCidara Therapeutics, Inc.COM NEW1,005,901$49.0M5.6%History
SLNOSoleno Therapeutics IncCOM186,250$15.6M1.8%History
THRDThird Harmonic Bio, Inc.COM1,915,424$10.4M1.2%History
ELVNEnliven Therapeutics, Inc.COM498,000$9.99M1.1%History
NKTRNektar TherapeuticsCOM NEW266,666$6.89M0.8%History
KURAKura Oncology, Inc.COM735,184$4.24M0.5%History
JBIOJade Biosciences, Inc.COM NEW64,023$639.6K0.1%History
CABACabaletta Bio, Inc.COM86,795$131.9K<0.1%History